Gamida Cell (NASDAQ:GMDA) announced its quarterly earnings data on Thursday. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.12, MarketWatch Earnings reports.
Gamida Cell stock opened at $5.30 on Friday. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average of $4.23 and a 200-day moving average of $4.43. Gamida Cell has a 1-year low of $2.60 and a 1-year high of $7.70.
GMDA has been the topic of a number of recent research reports. Needham & Company LLC reduced their price objective on Gamida Cell from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday. Oppenheimer raised their price objective on Gamida Cell from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Zacks Investment Research raised Gamida Cell from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, May 15th. HC Wainwright assumed coverage on Gamida Cell in a research note on Monday, April 27th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, BMO Capital Markets dropped their target price on shares of Gamida Cell from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Gamida Cell presently has a consensus rating of “Buy” and an average price target of $15.33.
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.